Table 1.
Anthropometric and clinical characteristics of patients and controls.
| CLSM | OCT and CLSM | |||
|---|---|---|---|---|
| Patients (10 f/18 m) | Controls (28 f/18 m) | Patients (10 f/16 m) | Controls (16 f/14 m) | |
| Age [year] | 14.2 ± 2.54 | 14.8 ± 1.89 | 14.5 ± 2.23 | 14.5 ± 1.98 |
| Height [SDS] | 0.06 ± 0.88 | 0.58 ± 1.20 | 0.15 ± 0.89 | 0.66 ± 1.20 |
| Weight [SDS] | 0.23 ± 0.93 | 0.46 ± 1.00 | 0.31 ± 0.97 | 0.59 ± 0.94 |
| BMI [SDS] | 0.25 ± 0.92 | 0.26 ± 0.84 | 0.30 ± 0.96 | 0.37 ± 0.80 |
| BPsys [SDS] | 1.94 ± 1.17* | 1.27 ± 1.16* | 1.95 ± 1.20 | 1.39 ± 1.18 |
| BPdias [SDS] | 0.89 ± 0.74* | 0.36 ± 0.88* | 0.90 ± 0.76 | 0.50 ± 0.97 |
| Duration of disease [year] | 4.23 (1.2–15.5) | 4.44 (1.2–15.5) | ||
| Mean daily insulin dosage [IU/kg] | 0.38 ± 0.15 | 0.39 ± 0.14 | ||
| Actual HbA1c [%] | 8.73 ± 2.00 | 8.96 ± 1.86 | ||
| Mean HbA1c [%] | 8.64 ± 1.53 | 8.73 ± 1.51 | ||
Results are given as mean ± standard deviation and as median (min, max) for all participants undergoing CLSM and for the subgroups undergoing OCT and CLSM. *Significant difference between patients and controls.